Eisai partners with C2N to build awareness and real-world evidence for blood-based testing in clinical trials Diagnosis of Patients with Cognitive Impairment in U.S. Clinical Practice Outside the Context
TOKYO, Aug. 24, 2022–(JCN Newswire)–Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has partnered with C2N Diagnostics (“C2N”) has signed a memorandum of understanding to raise awareness of how blood tests can diagnose patients with cognitive impairment (AD), including Alzheimer’s disease, and can help patients receive timely diagnosis and appropriate Treatment. Eisai Inc., in partnership with C2N, will work to raise awareness and develop real-world evidence to support the use of blood-based tests for patients with cognitive impairment in clinical practice outside of the U.S. clinical trial setting. Blood-based tests may lead to the development of new Clinical standard of care to provide timely and accurate diagnosis for patients with cognitive impairment. The number of people living with dementia is growing substantially; more than 55 million people worldwide have dementia, and this number is expected to increase to 78 million by 2030. (1) Accurate diagnosis remains a barrier to early and appropriate care management; research reviews estimate that 40% to 60% of adults at risk of dementia remain undiagnosed. (2) Importantly, blood-based tests may be able to help identify which patients may benefit from treatment, and thus may help simplify care and reduce healthcare spending. Early detection, diagnosis and treatment of dementia can protect individuals from the risk of delayed or missed diagnosis and allow individuals, their families and their caregivers to plan for the future as the disease progresses. (2) The development and adoption of blood-based tests as simple diagnostic tools in daily clinical practice is an important step in improving the care of people in remote and underserved communities where traditional diagnostic tools such as Positron emission tomography (PET) and lumbar puncture are not a viable option. Eisai will work with various partners to put simple, less invasive dementia diagnostic techniques and diagnostic methods (including blood tests) into practical use, and will work to improve dementia patients’ access to appropriate treatments healthcare environment, thereby contributing to the relief of dementia. Anxiety among people with dementia and their families worldwide. About C2N Diagnostics and its Blood-Based Cognitive Health Biomarkers C2N Diagnostics (“C2N”) is a specialty diagnostics company with a vision to bring clarity through innovation. C2N is committed to providing superior laboratory services and products in the field of brain health. C2N’s biomarker services and products are used to: make clinical decisions to improve patient care, including diagnosis and treatment monitoring; maximize the quality and efficiency of clinical trials testing new treatments for neurodegenerative diseases; and provide innovative tools to help healthcare Healthcare researchers better understand novel disease mechanisms, identify novel therapeutic targets, and conduct important epidemiological studies to improve global public health. Its PrecivityAD blood test is an innovative new blood test designed for patients with cognitive impairment. Using its mass spectrometry platform to accurately quantify the Abeta42/40 ratio and ApoE prototype in blood helps healthcare providers determine the presence of amyloid plaques in the brain, a hallmark hallmark of Alzheimer’s disease. In addition, the P-tau Multi-Analyte Assay (P-tau MAA), which simultaneously measures four types of phosphorylated and unphosphorylated forms of tau217 and tau181 in blood samples, is now available for Research Use Only (ROU). The assay is expected to aid in screening clinical studies, better understanding of disease biology, and investigational drug research. For more information, visit www.C2N.com (1) Alzheimer’s Disease International. World Alzheimer’s Report 2021, Dementia Diagnosis Journey. (2) Milken Institute. Building workforce capacity to improve detection and diagnosis of dementia in 2021. Media inquiries:
PR,
Eisai Co., Ltd.
+81-(0)3-3817-5120 Copyright © 2022 JCN Newswire. all rights reserved. A division of the Nippon Enterprise News Network.
